alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1
- PMID: 12192078
- PMCID: PMC2373593
- DOI: 10.1110/ps.0207302
alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1
Abstract
Coagulation and complement proteinases are activated in sepsis, and one approach to therapy is to develop proteinase inhibitors that will specifically inhibit these proteinases without inhibiting activated protein C, a proteinase that is beneficial to survival. In this study, we made mutants of the serpin alpha(1)-PI, designed to mimic the specificity of C1-inhibitor. The P3-P2-P1 residues of alpha1-PI were changed from IPM to LGR and PFR, sequences preferred by C1s and kallikrein, respectively. Inhibition of C1s, kallikrein, factor XIIa, and activated protein C was assessed by SDS-PAGE, and by determination of the k(app) and SI. alpha(1)-PI-LGR inhibited C1s with a rate of 7790 M(-1)s(-1), but only minimal inhibition of C1 in a hemolytic assay was observed. Kallikrein, factor XIIa, and activated protein C were inhibited with rates of 382,180 M(-1)s(-1), 10,400 M(-1)s(-1), and 3500 M(-1)s(-1), respectively. alpha(1)-PI-PFR was a poor inhibitor of C1s, factor XIIa, and activated protein C, but had enhanced reactivity with kallikrein. Changing the P4' residue of alpha(1)-PI-LGR Pro to Glu reduced the activity with C1s, consistent with the idea that C1s requires hydrophobic residues in this region of the serpin for optimal interaction. The data provide insight into the requirements for kallikrein and C1s inhibition necessary for designing inhibitors with appropriate properties for further investigation as therapeutic agents.
Figures


Similar articles
-
C1 inhibitor: analysis of the role of amino acid residues within the reactive center loop in target protease recognition.J Immunol. 2001 Aug 1;167(3):1500-6. doi: 10.4049/jimmunol.167.3.1500. J Immunol. 2001. PMID: 11466370
-
Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems.J Biol Chem. 1990 Jun 25;265(18):10786-91. J Biol Chem. 1990. PMID: 2191958
-
Functional characterization of the recombinant human C1 inhibitor serpin domain: insights into heparin binding.J Immunol. 2010 May 1;184(9):4982-9. doi: 10.4049/jimmunol.0902016. Epub 2010 Mar 29. J Immunol. 2010. PMID: 20351192
-
Biological activities of C1 inhibitor.Mol Immunol. 2008 Oct;45(16):4057-63. doi: 10.1016/j.molimm.2008.06.028. Epub 2008 Jul 31. Mol Immunol. 2008. PMID: 18674818 Free PMC article. Review.
-
Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.Adv Immunol. 2014;121:41-89. doi: 10.1016/B978-0-12-800100-4.00002-7. Adv Immunol. 2014. PMID: 24388213 Review.
Cited by
-
Therapeutic SERPINs: Improving on Nature.Front Cardiovasc Med. 2021 Mar 31;8:648349. doi: 10.3389/fcvm.2021.648349. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 33869308 Free PMC article. Review.
-
Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.Int J Mol Sci. 2022 Oct 19;23(20):12522. doi: 10.3390/ijms232012522. Int J Mol Sci. 2022. PMID: 36293378 Free PMC article.
-
Engineering the serpin α1 -antitrypsin: A diversity of goals and techniques.Protein Sci. 2020 Apr;29(4):856-871. doi: 10.1002/pro.3794. Epub 2019 Dec 9. Protein Sci. 2020. PMID: 31774589 Free PMC article. Review.
-
Targeted SERPIN (TaSER): A dual-action antithrombotic agent that targets platelets for SERPIN delivery.J Thromb Haemost. 2022 Feb;20(2):353-365. doi: 10.1111/jth.15554. Epub 2021 Oct 29. J Thromb Haemost. 2022. PMID: 34653316 Free PMC article.
-
Inhibition of post-mortem fish muscle softening and degradation using legume seed proteinase inhibitors.J Food Sci Technol. 2020 Jan;57(1):1-11. doi: 10.1007/s13197-019-04044-6. Epub 2019 Aug 24. J Food Sci Technol. 2020. PMID: 31975702 Free PMC article. Review.
References
-
- Bock, S.C., Skriver, K., Nielsen, E., Thogerson, H.C., Wiman, B., Donaldson, V.H., Eddy, R.L., Marrinan, J., Radziejewska, E., Huber, R., Shows, T.B., and Magnusson S. 1986. Human C1 inhibitor: Primary structure, cDNA cloning, and chromosomal localization.Biochemistry 25 4292–4301. - PubMed
-
- Busby, T.F., Atha, D.H., and Ingham, K.C. 1981. Thermal denaturation of antithrombin III. Stabilization by heparin and lyotropic anions.J. Biol. Chem. 256 12140–12147. - PubMed
-
- Caliezi, C., Wuillemin, W.A., Zeerleder, S., Redondo, M., Eisele, B., and Hack, C.E. 2000. C1-Esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema.Pharmacol. Rev. 52 91–112. - PubMed
-
- Carugati, A., Pappalardo, E., Zingale, L.C., and Cicardi, M. 2001. C1-inhibitor deficiency and angioedema.Mol. Immunol. 38 161–1739. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous